Komipharm International Co., Ltd. Share Price

Equities

A041960

KR7041960006

Pharmaceuticals

End-of-day quote Korea S.E. 03:30:00 30/04/2024 am IST 5-day change 1st Jan Change
4,155 KRW -0.48% Intraday chart for Komipharm International Co., Ltd. -0.84% -0.84%

Financials

Sales 2022 39.8B 29.17M 2.43B Sales 2023 42.65B 31.26M 2.61B Capitalization 294B 215M 17.97B
Net income 2022 -6.51B -4.77M -398M Net income 2023 -3.98B -2.92M -243M EV / Sales 2022 11.9 x
Net Debt 2022 27.33B 20.03M 1.67B Net Debt 2023 30.28B 22.2M 1.85B EV / Sales 2023 7.6 x
P/E ratio 2022
-68.5 x
P/E ratio 2023
-73.5 x
Employees 147
Yield 2022 *
-
Yield 2023
-
Free-Float 59.41%
More Fundamentals * Assessed data
Dynamic Chart
Komipharm International Co., Ltd. announces an Equity Buyback for 241,545 shares. CI
Komipharm International Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Komipharm International Co., Ltd. authorizes a Buyback Plan. CI
Komipharm International Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Komipharm International Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Komipharm International Co., Ltd. announced that it has received KRW 15 billion in funding from a group of investors CI
Komipharm International Co., Ltd. announced that it expects to receive KRW 15 billion in funding CI
Komipharm International Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Komipharm International Co., Ltd.'s Equity Buyback announced on September 23, 2022, has expired. CI
Tranche Update on Komipharm International Co., Ltd.'s Equity Buyback Plan announced on September 23, 2022. CI
Komipharm International Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Komipharm International Co., Ltd. announces an Equity Buyback for 146,842 shares. CI
Komipharm International Co., Ltd. authorizes a Buyback Plan. CI
Komipharm International Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Komipharm International Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
More news
1 day-0.48%
1 week-0.84%
Current month-8.78%
1 month-8.78%
3 months-6.21%
6 months-20.71%
Current year-0.84%
More quotes
1 week
4 090.00
Extreme 4090
4 235.00
1 month
4 040.00
Extreme 4040
4 755.00
Current year
4 000.00
Extreme 4000
4 940.00
1 year
3 735.00
Extreme 3735
7 649.75
3 years
3 735.00
Extreme 3735
14 763.47
5 years
3 735.00
Extreme 3735
26 528.83
10 years
3 735.00
Extreme 3735
47 510.56
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 26/93/26
Chief Executive Officer 70 27/88/27
Comptroller/Controller/Auditor 68 -
Members of the board TitleAgeSince
Chief Executive Officer 70 27/88/27
Chief Executive Officer 64 26/93/26
Director/Board Member 63 01/17/01
More insiders
Date Price Change Volume
02/24/02 4,160 +0.12% 42,240
30/24/30 4,155 -0.48% 57,197
29/24/29 4,175 -.--% 69,606
26/24/26 4,175 +0.85% 42,006
25/24/25 4,140 -0.12% 31,581

End-of-day quote Korea S.E., April 30, 2024

More quotes
Komipharm International Co Ltd is a Korea-based company principally engaged in the development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The Company’s main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The Company also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.
More about the company
  1. Stock Market
  2. Equities
  3. A041960 Stock